SION · Sionna Therapeutics, Inc.
$45.70
+2.58% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-16.2
Dividend yield
—
Beta
—
Avg volume
0M
Employees
0K
2D change
—
5D change
3.00%
10D change
-8.16%
30D change
7.59%
60D change
5.98%
MTD change
8.98%
YTD change
10.31%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SION
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-26
Latest call per bank · past 12 months
RBC Capital
Underperform$24.00
-47.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-26 | Citizens | Reiterates | Market Outperform | $63.00 |
| 2026-05-20 | Freedom Broker | Downgrade | Buy → Hold | $38.00 |
| 2026-05-18 | Stifel | Maintains | Buy | $44.00 → $55.00 |
| 2026-05-13 | BTIG | Reiterates | Buy | $58.00 |
| 2026-05-05 | Wedbush | Initiates | Outperform | $0.00 → $53.00 |
| 2026-04-28 | Jones Trading | Maintains | Buy | $52.00 → $63.00 |
| 2026-04-27 | BTIG | Reiterates | Buy | $58.00 |
| 2026-03-03 | Guggenheim | Maintains | Buy | $45.00 → $50.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.1% above the 50-day MA ($41.17).
- Price vs 200-day MA: Trading 17.9% above the 200-day MA ($39.48).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.08) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.76) and high ($49.41).
SION Price Chart
Loading chart for SION…
Fundamentals
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.